SUPN
Supernus Pharmaceuticals, Inc. (SUPN) Management Analysis (2026)
Overall Score
Capital Allocation
Management continues to prioritize balance-sheet strength, with current ratio at 2.08x and debt-to-equity at 0.04x.
Capital deployment remains conservative, as dividend yield is 0% and debt levels are minimal relative to market cap.
Free cash flow generation is still weak, with free cash flow yield at 0.7% and price-to-free-cash-flow at 143.7x.
Execution Operating Discipline
Operating execution remains challenged, with EBIT margin at -14.2% and net margin at -13.2%.
Working-capital efficiency is still poor, reflected in a 381.7-day cash conversion cycle and 309.3 days of inventory outstanding.
Gross margin remains strong at 88.1%, but it is not yet translating into positive operating profitability.
Governance Incentives
No new governance or incentive-related developments were reported this month.
The assessment remains anchored by the company’s conservative leverage profile and ongoing operating losses.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Supernus Pharmaceuticals, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

